Chen Zhihai said. Chen Zhihai

Chongqing brewery hepatitis b vaccine now uncovering blind hype is seen According to voice of the news aspect reported last week, the last two days, Chongqing Brewery's shares into a downturn in the stock market "Star", on Thursday on next day share price advance daily limit. Stir a lot of investors ' nerves. Great attention is exposed to the market, because Chongqing beer subsidiary is developing therapeutic hepatitis b vaccine solid experiment of phase II will be unveiled todayInspection result and application of space. Market optimism about results estimates made Chongqing Brewery's share price rises. Hepatitis b vaccine is not new, but this time, Chongqing brewery of therapeutic hepatitis b vaccine is said to enable e-Antigen negative conversion rates up to 40%, if so, it will be a major breakthrough on a hepatitis b treatment. But for this, members of the medical profession seems to be a much more calm。 So what is the medical profession's major breakthrough was to stimulate the stock price rose stunt? Reporter Andy Lau to the Secretary of the Board liaison to the Chongqing beer, not surprisingly, his answer was simple, and straightforward. Andy LAU: Sorry, announcement. Although Chongqing brewery knew little, but it was on October 30 to write research reports that it is expected that this experimental knotFruit that is: that "drugs can make the e Antigen negative conversion rates above 40%, high-dose group is likely to reach 50%". If they are really as speculation, as has often been we broke through as a hepatitis b treatment of problems of the world is, hepatitis b vaccine is not only prevention of disease in the traditional sense, has now become a weapon of the treatment of disease. Beijing Jin Baoyi Investment Management Ltd General Manager LiuLoyalty analysis, if once is true, will bring to Chongqing Brewery's shares of geometric growth. Liu Zhong: If the new drug registration is successful, should have a revolutionary impact. Chongqing brewery now yields very high, we care about is that it has concepts of hepatitis b vaccine listed, once listed on the new drug, it could fetch more than the number of levels, possibly geometry levelGrowth. Then press telephone interview the two clinicians, securities analysts ' optimism and vision, members of the medical profession about this show is more calm. Chen Zhihai, in the opinion of the second Ditan Hospital infection: first hepatitis b vaccine in the treatment of chronic hepatitis b it is not new, there are already many years, many people are "out of pocket" studies, and secondly, for this project, he said, They do not believe, does not mean that others do not believe, do not want to comment on this. Turning to the role of hepatitis b vaccine in the treatment, Chen Zhihai said. Chen Zhihai: our vaccines are active immunization, it is controlling our infection, for example, give you the vaccine then you produce antibodies, you will not be infected with hepatitis b virus. Now if you've been infected, and chronicThis virus has already integrated into your liver cells, this is a different matter, so active immunization vaccines are used to. Chen Zhihai stressed that a dozen years ago, chronic hepatitis b is not now or incurable diseases, already have very good drug treatments. Chen Zhihai: chronic hepatitis b have a very good solution now, if he does not know with the good guys didn'tWhat is the difference between, 70% don't need treatment, only 30% there will be problems. A dozen years ago, only the baogan method of liver disease, there are antiviral methods, duplicate suppression of virus, work very well. Graduated from China University of science and technology, College of life sciences the old republic power leveling, with a United States State doctorate in Biochemistry at the University of Michigan and the United States Department of biology at the University of Rochester, Soles grams of Salk Institute postdoctoral addition of Fang, when talking about the project, clearly expressed their skepticism. Fang: I do not believe that, or don't know how to treat hepatitis b hepatitis b vaccine. Seen from the reports could not say no problem, because it is only phase II clinical results, our drug is to go through three phases of clinical proved useful. Phase II can only be described as preliminary results, many of the drugs through phase II clinical, but found no effect in three phases, be weeded out, since the phase II drug is too small, so this alone is not to say alright, to go through phase III clinical. Phase III is the most critical, phase III publishing is valid, so for now, can't say the little problem of。 Starting from the Chongqing brewery in 1998 involved in hepatitis b vaccine, questioned has never subsided. A listed drug in Chongqing enterprises executives at once with all due respect, the development of new drugs failure rate is extremely high and hundreds of millions of dollars or even billions of dollars at every turn, Europe's leading pharmaceutical companies have not developed a hepatitis b vaccine alone Chongqing brewery billion yuan level input can be developed? It is worth noting is that while theCelebrate beer 11 directors have no medical background, but seems to remain optimistic about the future hepatitis b vaccine. There are a couple of hours, known experimental data will begin, and if successful swtor power leveling, Chongqing brewery will render multiple geometric growth in the market value, if fails, billions of market value will be implemented in the ashes bitter return value.